Afatinib price trends in 2025: will it be cheaper in the future?

Afatinib is a targeted drug used to treat EGFR mutation-positive non-small cell lung cancer (NSCLC) . It has been marketed in many countries and regions around the world, and has also been included in the scope of medical insurance reimbursement in China. As time goes by, patients are paying close attention to the price changes of afatinib and future trends. Especially after2025, whether the drug price will change is worth exploring.

The current market situation of afatinib in China is that it has been officially launched, and its drug price is more affordable for patients after being reimbursed by medical insurance. Nonetheless, because afatinib is an original drug developed and produced by Bayer in Germany, its price is relatively high. Taking the Indian market as an example, the original drug of afatinib is usually sold in the specifications of 40mg*28 tablets, with a price of about more than 5,000 yuan, and similar price levels exist in China.

Over time, drug prices are affected by several factors. First, the gradual emergence of generic drugs has put pressure on the prices of original drugs. Generic drugs of afatinib are currently on the market in some countries and regions, especially India, Laos and Bangladesh. The price of generic drugs is significantly lower than that of the brand-name drugs, which allows patients to have more economic choices when choosing afatinib. For example, the price of generic afatinib drugs in the Indian market is usually as low as a few hundred to more than 2,000 yuan, which is much cheaper than the original drug. The efficacy of these generic drugs is similar to that of the original drugs and the ingredients are basically the same, so they have a price advantage.

After 2025, the price of afatinib may face further changes, especially in the context of fierce competition in the global market, and the launch of generic drugs will pose a challenge to the price of the original drug. As more generic drugs enter the market, especially the production and sales of domestic generic drugs in China, the price of afatinib is likely to fall further.

Reference materials:https://www.giotrif.com/